Aelis Farma (FRA:69O) EPS (Diluted): €-0.47 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:69O Aelis Farma SA FRA:69O
32 GF Score
Price €1.05
GF Value €0.95
! 4 Warning Signs
View Full Analysis

What is Aelis Farma EPS (Diluted)?

Aelis Farma FRA:69O +4.37% 32 EPS (Diluted) is €-0.47 as of Dec. 2025. GuruFocus rates FRA:69O with a GF Score™ of 32/100 and a GF Value™ of €0.95. The stock has 4 warning signs investors should review.

Aelis Farma's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was €-0.15. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.47.

Aelis Farma's EPS (Basic) for the six months ended in Dec. 2025 was €-0.15. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.47.

Aelis Farma's EPS without NRI for the six months ended in Dec. 2025 was €-0.15. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.47.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Aelis Farma  (FRA:69O) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Aelis Farma EPS (Diluted) Related Terms

Aelis Farma EPS (Diluted) Historical Data

* Premium members only.

The historical data trend for Aelis Farma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aelis Farma EPS (Diluted) Chart

Aelis Farma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only 0.06 -1.21 -0.39 -0.55 -0.47

Aelis Farma Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 -0.27 -0.28 -0.32 -0.15

FRA:69O vs VRTX, REGN, ALNY: EPS (Diluted) Comparison

For the Biotechnology subindustry, Aelis Farma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aelis Farma PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aelis Farma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Aelis Farma's PE Ratio falls into.


FRA:69O
32GF Score
Aelis Farma SA FRA:69O
EPS (Diluted) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aelis Farma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Aelis Farma's Diluted EPS for the fiscal year that ended in Dec. 2025 is calculated as

Diluted EPS (A: Dec. 2025 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-6.434-0)/13.707
=-0.47

Aelis Farma's Diluted EPS for the quarter that ended in Dec. 2025 is calculated as

Diluted EPS (Q: Dec. 2025 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.111-0)/13.747
=-0.15

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Diluted) →
What does a EPS (Diluted) of €-0.47 mean?
Aelis Farma (FRA:69O) has a EPS (Diluted) of €-0.47 as of Dec. 2025. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Aelis Farma and its competitors.
Is Aelis Farma's EPS (Diluted) too high?
Aelis Farma's current EPS (Diluted) is €-0.47. Overall, Aelis Farma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Aelis Farma's EPS (Diluted) compare to VRTX and REGN?
Aelis Farma's EPS (Diluted) of €-0.47 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Biotechnology company?
A good EPS (Diluted) depends on the Biotechnology industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Aelis Farma and its competitors. Aelis Farma's current EPS (Diluted) is €-0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aelis Farma stock overvalued right now?
Aelis Farma (FRA:69O) has a current EPS (Diluted) of €-0.47. The stock's GF Value™ is €0.95, compared to a current price of €1.05 — trading 10.5% above its estimated fair value. The current EPS (Diluted) is €-0.47. Aelis Farma's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Aelis Farma (FRA:69O), the current EPS (Diluted) is €-0.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aelis Farma (FRA:69O) Overvalued in 2026?

Based on GuruFocus' analysis, Aelis Farma stock appears to be overvalued. The current stock price of €1.05 is trading 10.5% above its estimated GF Value™ of €0.95.

Key valuation signals for FRA:69O:

  • EPS (Diluted): €-0.47
  • GF Value™: €0.95 vs. price of €1.05 (10.5% above fair value)
  • GF Score™: 32/100 with 4 warning signs

No single metric tells the full story. See the FRA:69O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aelis Farma Business Description

Other Exchanges AELIS:France
Address 2 rue Robert Escarpit, IECB, Pessac, Bordeaux, FRA, 33607
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases. The Company operates in only one business segment: the research and development of pharmaceutical products.
32GF Score

Get the complete analysis for FRA:69O

EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.05
Price
€0.95
GF Value